Reducing skin calcium deposits with pyrophosphate
Part of Hormones & metabolism, Skin clinical trials.
This study tests whether an added treatment called pyrophosphate can reduce calcium deposits in the skin caused by systemic sclerosis (SSC). You may be able to join if you meet standard diagnosis criteria and don’t have certain heart- and thyroid-related issues.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must meet the ACR/EULAR diagnosis criteria for systemic sclerosis (SSC).
- You should not have severe upper gastrointestinal involvement (“upper misfestation”).
- You must not have an overactive thyroid or underactive thyroid.
- Your ECG must not show a prolonged QT interval (a heart rhythm timing issue).
- You may be asked to provide recent test results (diagnosis criteria, ECG, and thyroid labs).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This pilot study tests a medicine called sodium thiosulfate (given as a skin shot) to treat abnormal calcium or bone formation in places they don’t belong. It’s meant for people whose condition is causing significant problems, and who are not planning surgery for the next year.
This study tests whether the medicine clopidogrel can lower the chance of developing systemic sclerosis in adults who have certain blood antibodies and symptoms that suggest higher risk. If you qualify, you would take clopidogrel for the study to see whether it delays or prevents the disease.
This study will use CT scans to measure calcium deposits under the skin in people with scleroderma. It may help doctors better understand and track this condition.
This trial tests if injecting a medication called STS directly into calcium deposits can relieve pain and symptoms. It may help patients with scleroderma or related conditions who have painful calcium lumps.
This study tests whether blocking a protein called TL1A can help reduce skin thickening and improve the immune system in people with systemic sclerosis (a condition where skin becomes hard and thick). Researchers will compare skin and blood samples from people with systemic sclerosis to healthy volunteers.
This trial studies whether a treatment called rheopheresis, added to standard care, can help people with calciphylaxis whose skin wounds are getting worse. It may be considered when ulcers or dead (necrotic) skin appear despite conventional treatment.
Hear when a new Systemic Sclerosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.